Comparison 3. Souvenaid versus placebo in mild to moderate dementia due to Alzheimer's disease.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
3.1 Cognition: ADAS‐Cog	1	428	Mean Difference (IV, Fixed, 95% CI)	1.02 [‐1.11, 3.15]
3.2 Cognition: Global cognitive function composite score z‐score (4 components)	1	364	Mean Difference (IV, Fixed, 95% CI)	0.08 [‐0.07, 0.23]
3.3 Functional outcomes: ADCS‐ADL	1	451	Mean Difference (IV, Fixed, 95% CI)	0.51 [‐2.40, 3.42]
3.4 Combined cognitive‐functional outcome: CDR‐SoB	1	450	Mean Difference (IV, Fixed, 95% CI)	‐0.12 [‐0.74, 0.50]
3.5 General safety (follow up 24 weeks, all subjects treated population)	1		Risk Ratio (M‐H, Fixed, 95% CI)	Subtotals only
3.5.1 Any adverse event	1	524	Risk Ratio (M‐H, Fixed, 95% CI)	0.90 [0.78, 1.03]
3.5.2 Any serious adverse event	1	524	Risk Ratio (M‐H, Fixed, 95% CI)	0.78 [0.49, 1.26]
3.5.3 Dropout overall	1	527	Risk Ratio (M‐H, Fixed, 95% CI)	0.94 [0.62, 1.42]
3.5.4 Dropout due to (serious) adverse events	1	527	Risk Ratio (M‐H, Fixed, 95% CI)	0.49 [0.09, 2.68]